Company news

CAMP4 Therapeutics Corporation news in 2025

CAMP4 Therapeutics Corporation's news releases, calls and decks from 2025, newest first.

View company

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

December 18, 2025

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

December 18, 2025

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 12, 2025

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

November 6, 2025

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

October 1, 2025

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

September 10, 2025

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

August 19, 2025

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 14, 2025

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

May 16, 2025

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

May 13, 2025

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

April 28, 2025

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

March 27, 2025

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

March 18, 2025

Decks in 2025